What's he thinking about? Vivek Ramaswamy lines up a heavyweight title fight for a late-stage diabetes drug
Vivek Ramaswamy has carved out a late-stage alliance with a small biotech to take him into one of the most difficult big markets in the biopharma handbook.
Ramaswamy’s Roivant — the parent company to a lineup of “vant” startups — has agreed to pay Poxel $50 million in cash and up to $600 million in milestones to take their diabetes drug into Phase III in the world’s biggest markets. The upfront includes $15 million for an equity stake.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.